Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Receives Average Recommendation of “Reduce” from Analysts

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has earned a consensus rating of “Reduce” from the nine ratings firms that are covering the company, Marketbeat reports. Four analysts have rated the stock with a sell rating and five have issued a hold rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $28.00.

Several analysts recently issued reports on the stock. Erste Group Bank cut shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 5th. Citigroup reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Friday, April 24th. Wall Street Zen cut shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Morgan Stanley reaffirmed an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Wednesday, May 6th. Finally, Jefferies Financial Group raised shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “moderate sell” rating in a research note on Friday, May 8th.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Hedge funds have recently made changes to their positions in the company. CIBC Private Wealth Group LLC grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 398.2% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock valued at $36,000 after buying an additional 1,103 shares during the period. Arax Advisory Partners grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 121.6% in the 4th quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock valued at $38,000 after buying an additional 885 shares during the period. Kestra Advisory Services LLC purchased a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the 4th quarter valued at approximately $48,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the 4th quarter valued at approximately $58,000. Finally, Group One Trading LLC purchased a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the 3rd quarter valued at approximately $74,000. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Stock Up 1.4%

Shares of NYSE FMS opened at $22.51 on Friday. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $20.02 and a 12-month high of $29.71. The stock has a market cap of $12.57 billion, a PE ratio of 11.85, a P/E/G ratio of 4.01 and a beta of 0.81. The company has a current ratio of 1.20, a quick ratio of 0.86 and a debt-to-equity ratio of 0.40. The company has a 50-day moving average of $22.44 and a 200 day moving average of $23.08.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $1.05 earnings per share (EPS) for the quarter. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.88% and a return on equity of 8.90%. The company had revenue of $5.34 billion during the quarter. As a group, sell-side analysts predict that Fresenius Medical Care AG & Co. KGaA will post 2.24 EPS for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA Increases Dividend

The company also recently declared an annual dividend, which will be paid on Monday, June 8th. Stockholders of record on Friday, May 22nd will be paid a $0.8716 dividend. This is a positive change from Fresenius Medical Care AG & Co. KGaA’s previous annual dividend of $0.79. The ex-dividend date of this dividend is Friday, May 22nd. This represents a dividend yield of 387.0%. Fresenius Medical Care AG & Co. KGaA’s dividend payout ratio is currently 30.00%.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.